Literature DB >> 8744556

Treatment of aluminium hydroxide adjuvant to optimize the adsorption of basic proteins.

J V Rinella1, J L White, S L Hem.   

Abstract

Aluminium hydroxide adjuvant has an isoelectric point (i.e.p.) of ca 11 and is a good adsorbent for acidic proteins due to the contribution of electrostatic attractive forces. However, electrostatic repulsive forces reduce its ability to adsorb basic proteins. Pretreatment of aluminium hydroxide adjuvant with carefully selected concentrations of phosphate anion reduces the positive surface charge which exists at pH 7.4. Treatment with higher concentrations of phosphate anion produces a negative surface charge. The adsorption of lysozyme (i.e.p = 11.1) was found to be directly related to the concentration of phosphate anion used to pretreat the aluminium hydroxide adjuvant.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8744556     DOI： 10.1016/0264-410x(95)00194-6

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  8 in total

1.  Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model.

Authors:  Karen A Near; Anthony W Stowers; Dragana Jankovic; David C Kaslow
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

2.  A method of lyophilizing vaccines containing aluminum salts into a dry powder without causing particle aggregation or decreasing the immunogenicity following reconstitution.

Authors:  Xinran Li; Sachin G Thakkar; Tinashe B Ruwona; Robert O Williams; Zhengrong Cui
Journal:  J Control Release       Date:  2015-02-28       Impact factor: 9.776

Review 3.  Advances in aluminum hydroxide-based adjuvant research and its mechanism.

Authors:  Peng He; Yening Zou; Zhongyu Hu
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 4.  Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability.

Authors:  Tanya Clapp; Paul Siebert; Dexiang Chen; LaToya Jones Braun
Journal:  J Pharm Sci       Date:  2010-08-25       Impact factor: 3.534

5.  Increasing the potency of an alhydrogel-formulated anthrax vaccine by minimizing antigen-adjuvant interactions.

Authors:  Allan Watkinson; Andrei Soliakov; Ashok Ganesan; Karie Hirst; Chris Lebutt; Kelly Fleetwood; Peter C Fusco; Thomas R Fuerst; Jeremy H Lakey
Journal:  Clin Vaccine Immunol       Date:  2013-08-28

6.  Efficient extraction of vaccines formulated in aluminum hydroxide gel by including surfactants in the extraction buffer.

Authors:  Daming Zhu; Shuhui Huang; Holly McClellan; Weili Dai; Najam R Syed; Elizabeth Gebregeorgis; Kelly M Rausch; Gregory E D Mullen; Carole Long; Laura B Martin; David Narum; Patrick Duffy; Louis H Miller; Allan Saul
Journal:  Vaccine       Date:  2011-11-19       Impact factor: 3.641

7.  Enhancement of humoral immunity in mice by coupling pUCpGs10 and aluminium to the HCV recombinant immunogen.

Authors:  Na Zhan; Bing S Xiu; Guo H Wang; Kun Chen; Guan Z Bai; Xiao G Song; Cui X Zhu; Zhen H Dai; Xi Q Yang; He Q Zhang
Journal:  Virol J       Date:  2011-11-04       Impact factor: 4.099

8.  Effect of Aluminum Adjuvant and Preservatives on Structural Integrity and Physicochemical Stability Profiles of Three Recombinant Subunit Rotavirus Vaccine Antigens.

Authors:  Sanjeev Agarwal; John M Hickey; David McAdams; Jessica A White; Robert Sitrin; Lakshmi Khandke; Stanley Cryz; Sangeeta B Joshi; David B Volkin
Journal:  J Pharm Sci       Date:  2019-10-04       Impact factor: 3.534
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.